Johns Hopkins University, Dept. of Biostatistics Working Papers

7-23-2008

A NOVEL AND SIMPLE RULE OF THUMB
FOR MULTIPLICITY CONTROL IN
EQUIVALENCE TESTING USING TWO
ONE-SIDED TESTS
Carolyn Lauzon
Department of Biophysics, Johns Hopkins University

Brian S. Caffo
Department of Biostatistics, The Johns Hopkins Bloomberg School of Public Health, bcaffo@jhsph.edu

Suggested Citation
Lauzon, Carolyn and Caffo, Brian S., "A NOVEL AND SIMPLE RULE OF THUMB FOR MULTIPLICITY CONTROL IN
EQUIVALENCE TESTING USING TWO ONE-SIDED TESTS" ( July 2008). Johns Hopkins University, Dept. of Biostatistics Working
Papers. Working Paper 172.
http://biostats.bepress.com/jhubiostat/paper172

This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the
copyright holder.
Copyright © 2011 by the authors

A Novel and Simple Rule of Thumb for Multiplicity
Control in Equivalence Testing Using Two
One-sided Tests
Carolyn Lauzon and Brian Caffo
Department of Biophysics and Department of Biostatistics
Johns Hopkins University
July 23, 2008

Abstract
Equivalence testing is growing in use in scientific research outside of its traditional
role in the drug approval process. Largely due to its ease of use and recommendation
from the United States Food and Drug Administration guidance, the most common
statistical method for testing (bio)equivalence is the two one-sided tests procedure
(TOST). Like classical point-null hypothesis testing, TOST is subject to multiplicity
concerns as more comparisons are made. In this manuscript, a condition that bounds
the family-wise error rate (FWER) using TOST is given. This condition then leads to a
simple solution for controlling the FWER. Specifically, we demonstrate that if all pairwise comparisons of k independent groups are being evaluated for equivalence, then
simply scaling the nominal Type I error rate down by (k − 1) is sufficient to maintain
the family-wise error rate at the desired value or less. The resulting rule is much less
conservative than the equally simple Bonferroni correction. An example of equivalence
testing in a non drug-development setting is given.
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1 Introduction
Broadly speaking, scientific research is often thought of as a field that is interested in inductively demonstrating differences between experimental groups while presuming equality
under a null (status quo) hypothesis. However, often scientists are not interested in establishing differences, but in proving similarities. It is our experience that questions of
similarity or equivalence are as fundamentally important to scientific research as those of
differences.
An important example is that of demonstrating the bioequivalence of two drugs, such
as an established brand name drug and a new generic equivalent. Bioequivalence refers
to establishing a lack of differences in absorption as measured by blood concentration, of
two such formulations. Hence, the natural null hypothesis is that the two formulations
have different absorption rates on a scale that is biologically relevant. Typically, the metrics being compared are natural logarithms of areas under a plasma/concentration curves
obtained by repeated blood samples of subjects having received both drugs in a random
order (with a suitable washout period).
We refer to this form of evaluation in the drug approval setting as bioequivalence and
reserve the term equivalence for more generic settings. Establishing equivalence generally
follows two steps; i) first, a setting-specific meaningful difference in population parameters
between two groups is selected and ii) statistical inference is used to establish whether
empirical estimates of the parameters are fall within the bounds of the meaningful limits.
Early related work on equivalence testing using symmetric intervals can be found in
Westlake (1976). Anderson and Hauck (1983) and Hauck and Anderson (1984) give
a more powerful method for a two-way crossover design. Since these early influential
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articles, new procedures have been developed based on likelihood intervals (Choi et al.,
2007), Bayesian credible intervals (Selwyn and Hall, 1984; Selwyn et al., 1981; Fluehler
et al., 1983) and alternative frequentist tests and intervals (Berger and Hsu, 1996; Hsu
et al., 1994; Brown et al., 1995), to name a few.
Certainly the most widely used procedure for statistically evaluating equivalence is the
two one-sided tests procedure (TOST), which is advocated by the US FDA for establishing
bioequivalence. TOST is a form of equivalence testing proposed by Schuirmann (1987).
Part of TOST’s popularity is that it is theoretically and operationally similar to classical
normal-theory hypothesis testing of the equality of population means. Despite their close
relationship and the ubiquity of (alternative) research hypotheses of similarity, TOST has
been mostly unused in the non-drug development scientific community at large, where
classical point-null hypothesis testing of population means is firmly entrenched. A possible
reason for the large disparity in usage is not one of utility, but of exposure. Perhaps the
greatest evidence supporting this explanation is the frequent misapplication of post-hoc
power calculations to data that should be analyzed using equivalence testing (Hoenig and
Heisey, 2001; Goodman and Berlin, 1994).
Recently, equivalence testing has made inroads in scientific applications unrelated to
drug development (Barnett et al., 2007, 2006). In fact, research papers advocating the
use of equivalence testing in a diverse collection of fields have begun to appear (Barker
et al., 2002; Tempelman, 2004). We conjecture that as awareness of equivalence testing
increases, so will the number of scientists incorporating TOST into their regular statistical
toolbox. Hence, it is necessary to develop methods for adapting TOST to the diverse
situations scientific data can present.
One example addressed here is that of multiplicity. As in classical hypothesis testing,
as more means are compared, the family-wise error rate, the probability of at least one
incorrectly rejected null in an family of tests, αF , rises above that of the set nominal type
I error rate, αN . If enough means are compared, the family-wise error rate becomes un-
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acceptably high and must be controlled. Because the foundation for equivalence testing is
the same as that of classical hypothesis testing, we look to existing solutions for addressing
multiplicity. In order to adapt these solutions a more explicit knowledge of equivalence
testing is necessary.

2 Bioequivalence theory
For simplicity, we describe the TOST procedure for comparing two independent group
means from normally distributed data, presuming a common variance and equal sample sizes. This setting for equivalence testing has been described in detail elsewhere
(Schuirmann, 1987). Briefly, equivalence testing seeks to test if the difference between the
two population means, ∆µ, is within some previously defined tolerance interval [θl , θu ]. To
do this, two sets of disjoint hypotheses are formed. Closely following the description and
notation in Schuirmann’s original manuscript, we have:
null hypothesis

H01 : µ ≤ θl or

H02 : µ ≥ θu

(1)

alternative hypothesis Ha1 : µ > θl and Ha2 : µ < θu ,
From each pair of hypotheses, test statistics are formed and compared to critical values
from Gossett’s T distribution. Specifically, H01 and H02 are rejected if
∆X̄ − θl
p
> tdf,1−α
s 2/n

(2)

θu − ∆X̄
p
> tdf,1−α
s 2/n

(3)

and

respectively; where ∆X̄ is the observed difference in means between the two groups, s is
the pooled standard deviation (hence we’re assuming a common variance across the two
groups), n is the (assumed common) sample size per group, df is the degrees of freedom
and ta,b is the b quantile from Gossett’s T distribution with a degrees of freedom. The TOST
procedure states that if both 2 and 3 are true, then the means are declared equivalent.
4
http://biostats.bepress.com/jhubiostat/paper172

p
Equivalently, test (2) rejects if the lower confidence bound ∆X̄ − tdf,1−αN s/ 2/n is above
p
θl and test (3) rejects if the upper confidence bound ∆X̄ + tdf,1−αN s/ 2/n is below θu .
Hence, the two one sided test procedure is identical to forming the corresponding (1−2αN )
confidence interval and declaring the two groups equivalent if the interval lies entirely
within the tolerance limits. Note that there has been discussion in the literature on whether
a (1 − 2αN ) or (1 − αN ) interval should be used. We adopt the former, though emphasize
that our conclusions do not depend on this choice.
For simplicity of the discussion, we assume that the toleration limit is symmetrically
centered around zero; that is −θl = θu = θ. Then the hypotheses (1) can be restated as
H0 : |∆µ| ≥ θ versus Ha : |∆µ| < θ
and equations (2) and (3) are restated as
θ − ∆X̄
∆X̄ + θ
p
> tdf,1−αN and p
> tdf,1−αN .
s 2/n
s 2/n

(4)

3 Family-wise error rates for all pair-wise comparisons
A common solution in classical hypothesis testing for handling family-wise error rates is
the Bonferroni correction. This correction is widely used because of its simplicity. It is
based on the fact that the probability of at least one incorrectly rejected null hypothesis in
a collection of tests is bounded by the sum of the probabilities of the individual type I error
rates. For example if all pair-wise tests are being performed for k groups, each comparison
made with a type I error rate of αN , then the actual family-wise error rate, αF follows:
 
 k 
αF ≤ αN   = αN k(k − 1)/2
(5)
2
Therefore, if αD is a desired family-wise error rate, then setting αN =

2αD
k(k−1)

bounds the

actual family-wise error rate by the desired one. Depending on the setting, this procedure
can be very conservative, especially when the outcomes of the tests are correlated. We
5
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further note that the Bonferroni correction applies without modification to equivalence
testing; one simply divides the error rate by the number of tests performed.
We seek a less conservative method of multiplicity control. Though relevant research
in multiple comparisons (see Giani and Strassburger, 2000; Bofinger, 1985; Giani and
Strassburger, 1994; Hsu, 1996) may produce more optimal solutions, our interest lies in
simple rules that are easily motivated and implemented.
Under our assumptions, in a standard point null hypothesis, the desired type I error
rate is obtained exactly. In equivalence testing using TOST, the null hypothesis includes
a range of possible parameter values, and hence the desired type I error rate is obtained
only on the boundary of the null parameter space (Schuirmann, 1987). Hence, one attains
the type I error rate exactly only when |∆µ| = θ and even then only as a limit as the effect
size tends to infinity. Otherwise, the procedure is conservative.
Consider again the setting where all pair-wise comparisons are being made of k groups,
each with a population mean µi for i = 1, . . . , k. Without loss of generality, we presume
that the means are ordered from least to greatest. If all tests satisfy the null hypothesis,
then the means must be at least θ apart. The maximum type I error rate for each comparison is then obtained only when the means are exactly θ apart. That is, µi − µi−1 = θ
for i = 2, . . . , k. We note that this scenario maximizes the family-wise error rate because:
decreasing the length between any two adjacent means renders them equivalent (a violation of the assumption that all null hypotheses are true) while expanding the distances
decreases the individual type I error rates (hence decreasing the family-wise error rate).
Note that a Bonferroni correction based on (5) accounts for all possible comparisons,
even of the most distal means, which must be at least k − 1 times the tolerance limit
apart. More specifically, observe that in the most conservative scenario, where the ordered
means are exactly θ apart, (k −1) comparisons occur with a true difference ∆µ = 1θ, (k −2)
comparisons with a true difference ∆µ = 2θ and in general (k − `) comparisons are made
with a true difference ∆µ = `θ.
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Let α` be the actual type I error rate for the bioequivalence test performed for a comparison with ∆µ = `θ. This parameter is derived and discussed in Appendix A. Under this
setting, α1 is closest to αN and limits to αN (see Section 4 and Appendix A). Furthermore,
α` < αN for all ` > 1. Also recall that the Bonferroni inequality states that the family-wise
error rate is less than the sum of the individual error rates: then, αF can be no greater
than the sum of the α` times the number of comparisons with true difference in the means
equal to ` . That is,
αF ≤

k−1
X

α` (k − `).

(6)

`=1

The more conservative bound (5) is obtained by the fact that α` < α1 < αN . Since bounding αF by adding the individual error rates is already a conservative procedure, and the α`
decrease exponentially as ` increases, using the bound (5) is excessively conservative.
Creating a more accurate Bonferroni bound is not conceptually difficult, but it lacks the
typical computational ease of the naive Bonferroni correction (5). Specifically, an upper
bound on each α` , say α̃` , can be obtained numerically (for fixed values of n, k and αN )
by maximizing over the effect size, θ/σ, where σ is the common group-specific standard
deviation. Then, the equation:
αD =

k−1
X

α̃` (k − `)

(7)

`=1

could be solved by modifying αN to obtain the desired αD , such as by a bisection algorithm.
Evaluations of the family wise error rates for a variety of effect sizes (described below)
illustrates that the first term, α1 (k − 1), is close to αN (k − 1) and completely dominates the
right hand side of equation (6). Hence, a convenient and simple rule of thumb is to set αN
to αD /(k − 1). We refer to this multiple comparisons procedure as an `-correction. Thus
we contend that the naive Bonferroni procedure unnecessarily divides αD by a factor of
k/2. Below, we evaluate this rule of thumb and demonstrate that is much less conservative
than a naive Bonferroni correction and is nearly equivalent to a correction based on (6).
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4 Numerical evaluations
As is argued in Appendix A, we first note that α1 limits to αN as the effect size increases.

 p
Figure 1 displays the behavior of α1 as a function of the parameter ∇ = 2θ/ σ 2/n .
We chose this parameter rather than the effect size to match the notation of Schuirmann
(1987). This figure illustrates that α1 tends to the nominal error rate. Because of the
square-root n in the denominator of the denominator of ∇, α1 will typically be near αN .
Note that in this figure, and the remaining, the smallest possible degrees of freedom under
our assumptions (2n − 2) was used.
Figure 2 displays the rapid decrease in error rate for those tests whose mean difference
is ∆µ = 2θ. Note that the maximum magnitude of these terms, α̃2 , is on the order of 10−4 .
Plots for larger values of ` are not shown, as their shape is similar with a rapidly decreasing
maximum value. Figure 3 displays this decrease, by plotting α̃` as ` increases.
Table 1 displays the bounds on the family-wise error rate for various values of n and
k. This table shows the extreme conservatism of the naive Bonferroni bound (5), which is
often well above 1. As it is also obtained by adding error rates, the bound based on (7)
remains quite conservative, though is much less so than the naive Bonferroni bound. The
next to the last column illustrates that the first term of (7) dominates the sum.

5 Example
We demonstrate the `-correction on an example from the field of cell-engineering. Recently, scientists have been interested in comparing the effects of different labeling agents
on what are called microcapsules (Barnett et al., 2007). Briefly, the function of a microcapsule is to deliver and house healthy xenogenic cells in patients whose own cells do
not function properly, such as injecting porcine pancreatic cells into patients with type II
diabetes. In order to monitor microcapsules once inside patients, labels that are either
MRI (magnetic resonance imaging), ultrasound or X-ray visible are added to the micro8
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capsules. However, researchers must asses the labels effect on the living cells inside the
microcapsule. In one currently unpublished study, a human hepatic cell line (Hep G2
ATCC, Manassas) was encapsulated in contrast containing polyethylene glycol diacrylate
microcapsules and their viability under 6 different labeling conditions was assessed. Included in this study was also an unlabeled control, making a total of 7 different conditions.
The researchers were concerned with ensuring that the inclusion of contrast agent did not
significantly alter viability of encapsulated cells and in assessing if cells were equally viable
under the different labeling conditions. Hence, interest lies in testing biological equivalent
viability between different labels in order to asses switch-ability. To test viability, cell survival was assessed at different time points after cell encapsulation and equivalence testing
performed. Setting θ to 5%, all pairwise TOST test were performed, comparing all strata
to each other at each time point. The result is a total of 21 comparisons per time point.
In Table 2 the larger of the two confidence endpoints, in absolute value, is given, both
using the `-correction and the naive Bonferroni correction. The TOST test could be performed for each by comparing these numbers to the tolerance limit. The 5% tolerance limit
bound is above this upper value on several comparisons. Most importantly, the result of
the test reverses after use of the less conservative multiplicity control in the comparisons:
(1, 2), (5, 2), (7, 2), and (6, 4)

6

Conclusion

The proposed `-correction, simply setting the nominal error rate used in TOST to the
desired family-wise error rate divided by one minus the number of groups compared, provides a fast and simple rule of thumb for testing the bioequivalence of multiple strata. The
basis for this approach comes from a bound on the family-wise error rate by adding the
individual error rates and noting that under a joint null-hypothesis for comparisons, only
the k − 1 comparisons with the closest mean differences make any real contribution to
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this bound. On a practical side, it is important to note that in the case where all strata
are compared to a single control, the `-correction and naive Bonferroni correction will be
identical. However, in examples where all pairwise comparisons are made, such as the one
considered above, the `-correction will achieve a much tighter bound to the family-wise
error rate.
We emphasize that, while a vast improvement over a naive Bonferroni correction, the
proposed `-correction is motivated by adding error rates and hence can be very conservative. Its main attractions are its ease of explanation and simple implementation. If these
rationals are not of interest in the problem in hand, more optimal procedures should be
pursued.
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A Derivation of α`
We presume that the true value of ∆µ is `θ and, for brevity, we denote the critical value
tdf,1−αN simply by t.
!
θ − ∆X̄
∆X̄ + θ
p
p
> t and
>t
s 2/n
s 2/n
r
θ(1 − `)
t
s2 df
∆X̄ − `θ
p
−√
and
> p
2
σ
df
σ 2/n
σ 2/n

α` = P
= P

t
θ(1 − `)
p
− √ χ2df > Z and
df
σ 2/n

= P
"

= E P

θ(1 + `)
t
− p
+√
df
σ 2/n
!
θ(1 + `)
t
− p
+ √ χ2df < Z
df
σ 2/n

θ(1 − `)
t
p
− √ χ2df > Z and
df
σ 2/n

t
θ(1 + `)
+ √ χ2df < Z
− p
df
σ 2/n

r

s2 df
∆X̄ − `θ
< p
2
σ
σ 2/n

!

!#
χ2df

where, recall, df refers to the degrees of freedom and χ2df and Z represent independent chisquared and Z random variables, respectively. A simple calculation yields that the interior
probability is greater than zero only when
"(
α` = E

Φ

t
θ(1 − `)
p
− √ χ2df
df
σ 2/n

!

θ2 df
t2 σ 2 2/n

> χ2df . Hence this may be written as:

!) 
#
2
t
θ(1 + `)
θ df
+ √ χ2df
−Φ − p
I 2 2
> χ2df
,
t σ 2/n
df
σ 2/n

where I(·) is an indicator function. This formula was used for all calculations, with GaussLaguerre integration (see Press et al., 1992), implemented in R (Ihaka and Gentleman,
1996), used for the outer expectation.
Several points are in order: i) because of the indicator function, this is not the difference between two non-central T probabilities; ii) the only unknown that this equation
depends on is the effect size θ/σ; iii) the larger ` is, the smaller the two interior normal
distribution probabilities are. iv) small values of θ/σ will restrict the area of integration,
hence yielding small probabilities; v) for ` > 1, large values of θ/σ will yield small probabilities for the interior normal distributions. Hence for ` > 1, this probability will typically be
very small, and decays exponentially fast as ` increases. Finally for ` = 1, as θ/σ increases,
the left normal term limits to αN while the right one limits to 0.
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B Tables
Bound based on (7) for given value of n

Naive
(k − 1)αn

Bonferroni

.2513 .2509 .2509 .2508 .2508 .2508

0.25

0.75

12 .5524 .5521 .5520 .5520 .5520 .5520

0.55

3.30

20 .9538 .9536 .9536 .9536 .9536 .9536

0.95

9.50

k
6

5

10

15

20

50

1000

Table 1: Values for bounds on the family-wise error rate when setting αN = .05 for various
values of n and k. The first columns give the bound based on (7) while the second to the
last column only uses the first term, (k − 1)αN and the naive Bonferroni correction is based
on (5).

1
1

-

2 4.52

2

3

4

5

6

7

5.49 7.39 6.34 4.44 6.36 4.95
-

3 6.44 6.86

7.92 7.43 5.43 7.54 5.77
-

4 5.55 6.43 8.35

9.34 7.33 9.44 7.69
-

5 3.68 4.45 6.38 5.65

6.49 5.01 6.93
-

6 5.58 6.57 8.49 4.16 5.72

6.52 4.89
-

7 4.07 4.75 6.68 6.01 4.01 6.12

7.01
-

Table 2: The maximum of the absolute value of the confidence interval for ∆µ for the
example 5. Hence a TOST test can be performed by comparing each number to the tolerance limit. Here the limits using the `-correction are given below the diagonal while
the limits using the naive Bonferroni are given above the diagonal. For example, the [3, 1]
and [1, 3] cells give the comparison of groups one and three for the `-correction and naive
Bonferroni, respectively.
14
http://biostats.bepress.com/jhubiostat/paper172

C Figures

Figure 1: The true error rate, α1 , for a TOST test performed when ∆µ = 1θ plotp
ted as a function of 2θ/σ 2/n. Each line represents a different sample size with
n = 5, 10, 15, 20, 50, 1000. The arrows point in the direction of increasing n.
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Figure 2: The true error rate, α2 , for a TOST test performed when ∆µ = 2θ plotp
ted as a function of 2θ/σ 2/n. Each line represents a different sample size with
n = 5, 10, 15, 20, 50, 1000. The shape for the ` = 2 case is representative of the shapes
of all plots for any case ` > 1. The arrow points in the direction of increasing n.
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Figure 3: The maximum true alpha rates, α̃` , for a TOST test performed between two
distributions whose means are `θ apart are shown for the six different sample sizes n =
5, 10, 15, 20, 50, 1000. Here ` is labeled “index” on the horizontal axis. A tolerance limit of
five decimal places was used in the calculation of the maximums. The arrows point in the
direction of increasing n.
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